{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:26:39Z","timestamp":1786980399019,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00467-026-07254-1","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T13:59:06Z","timestamp":1773669546000},"page":"3315-3331","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison between effectiveness and safety of plasma therapy and complement inhibitors for the treatment of atypical hemolytic uremic syndrome: a systematic review and meta-analysis of real-world data"],"prefix":"10.1007","volume":"41","author":[{"given":"Thy Phuong Anh","family":"Le","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana Tze-Wah","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Yi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1994-834X","authenticated-orcid":false,"given":"Ka-Wai","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"key":"7254_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/1744-9987.12763","volume":"23","author":"R Raina","year":"2019","unstructured":"Raina R, Krishnappa V, Blaha T et al (2019) Atypical hemolytic-uremic syndrome: an update on pathophysiology, diagnosis, and treatment. Ther Apher Dial 23:4\u201321. https:\/\/doi.org\/10.1111\/1744-9987.12763","journal-title":"Ther Apher Dial"},{"key":"7254_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2025.107714","volume":"216","author":"ED Stea","year":"2025","unstructured":"Stea ED, Pugliano M, Gualtierotti R et al (2025) Multidisciplinary consensus on the diagnosis and management of patients with atypical hemolytic uremic syndrome (complement-mediated TMA): recommendations from Italian scientific societies, patient associations and regulators. Pharmacol Res 216:107714. https:\/\/doi.org\/10.1016\/j.phrs.2025.107714","journal-title":"Pharmacol Res"},{"key":"7254_CR3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/ijlh.13954","volume":"44","author":"GL Thompson","year":"2022","unstructured":"Thompson GL, Kavanagh D (2022) Diagnosis and treatment of thrombotic microangiopathy. Int J Lab Hematol 44:101\u2013113. https:\/\/doi.org\/10.1111\/ijlh.13954","journal-title":"Int J Lab Hematol"},{"key":"7254_CR4","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3339\/ckd.25.017","volume":"29","author":"JY Song","year":"2025","unstructured":"Song JY (2025) Atypical hemolytic uremic syndrome: pathophysiology, clinical presentation, and treatment strategies. Child Kidney Dis 29:52\u201359. https:\/\/doi.org\/10.3339\/ckd.25.017","journal-title":"Child Kidney Dis"},{"key":"7254_CR5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00467-015-3076-8","volume":"31","author":"C Loirat","year":"2016","unstructured":"Loirat C, Fakhouri F, Ariceta G et al (2016) An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol 31:15\u201339. https:\/\/doi.org\/10.1007\/s00467-015-3076-8","journal-title":"Pediatr Nephrol"},{"key":"7254_CR6","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.jfma.2022.10.006","volume":"122","author":"MH Tseng","year":"2023","unstructured":"Tseng MH, Lin SH, Tsai JD et al (2023) Atypical hemolytic uremic syndrome: consensus of diagnosis and treatment in Taiwan. J Formos Med Assoc 122:366\u2013375. https:\/\/doi.org\/10.1016\/j.jfma.2022.10.006","journal-title":"J Formos Med Assoc"},{"key":"7254_CR7","doi-asserted-by":"publisher","first-page":"e20240087","DOI":"10.1590\/2175-8239-jbn-2024-0087en","volume":"47","author":"MH Vaisbich","year":"2025","unstructured":"Vaisbich MH, De Andrade LGM, De Holanda Barbosa MIN et al (2025) Recommendations for diagnosis and treatment of atypical hemolytic uremic syndrome (aHUS): an expert consensus statement from the Rare Diseases Committee of the Brazilian Society of Nephrology (COMDORA-SBN). Braz J Nephrol 47:e20240087. https:\/\/doi.org\/10.1590\/2175-8239-jbn-2024-0087en","journal-title":"Braz J Nephrol"},{"key":"7254_CR8","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1007\/s00467-019-04233-7","volume":"34","author":"A Bagga","year":"2019","unstructured":"Bagga A, Khandelwal P, Mishra K et al (2019) Hemolytic uremic syndrome in a developing country: consensus guidelines. Pediatr Nephrol 34:1465\u20131482. https:\/\/doi.org\/10.1007\/s00467-019-04233-7","journal-title":"Pediatr Nephrol"},{"key":"7254_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"7254_CR10","unstructured":"Wells GA, Shea B, O'Connell D et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute.  https:\/\/ohri.ca\/en\/who-we-are\/core-facilities-and-platforms\/ottawa-methods-centre\/newcastle-ottawa-scale.  Accessed 7 Dec 2025"},{"key":"7254_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/cells10123580","volume":"10","author":"R Raina","year":"2021","unstructured":"Raina R, Vijayvargiya N, Khooblall A et al (2021) Pediatric atypical hemolytic uremic syndrome advances. Cells 10:3580. https:\/\/doi.org\/10.3390\/cells10123580","journal-title":"Cells"},{"key":"7254_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/kisup.2012.73","volume":"3","author":"KDIGO","year":"2012","unstructured":"KDIGO (2012) Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3:1\u2013150. https:\/\/doi.org\/10.1038\/kisup.2012.73","journal-title":"Kidney Int Suppl"},{"key":"7254_CR13","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R Dersimonian","year":"1986","unstructured":"Dersimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177\u2013188. https:\/\/doi.org\/10.1016\/0197-2456(86)90046-2","journal-title":"Control Clin Trials"},{"key":"7254_CR14","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1016\/j.ekir.2019.07.016","volume":"4","author":"E Rondeau","year":"2019","unstructured":"Rondeau E, Cataland SR, Al-Dakkak I, Miller B, Webb NJA, Landau D (2019) Eculizumab safety: five-year experience from the global atypical hemolytic uremic syndrome registry. Kidney Int Rep 4:1568\u20131576. https:\/\/doi.org\/10.1016\/j.ekir.2019.07.016","journal-title":"Kidney Int Rep"},{"key":"7254_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-016-0420-6","volume":"18","author":"N Besbas","year":"2017","unstructured":"Besbas N, Gulhan B, Soylemezoglu O et al (2017) Turkish pediatric atypical hemolytic uremic syndrome registry: initial analysis of 146 patients. BMC Nephrol 18:6. https:\/\/doi.org\/10.1186\/s12882-016-0420-6","journal-title":"BMC Nephrol"},{"key":"7254_CR16","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s12519-017-0021-x","volume":"13","author":"SA Zhao","year":"2017","unstructured":"Zhao SA, Ning BT, Mao JH (2017) Clinical characteristics of children with hemolytic uremic syndrome in Hangzhou, China. World J Pediatr 13:183\u2013185. https:\/\/doi.org\/10.1007\/s12519-017-0021-x","journal-title":"World J Pediatr"},{"key":"7254_CR17","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/nep.14004","volume":"27","author":"S Kandari","year":"2022","unstructured":"Kandari S, Chakurkar V, Gaikwad S, Agarwal M, Phadke N, Lobo V (2022) High prevalence of CFHR deletions in Indian women with pregnancy-associated hemolytic uremic syndrome. Nephrology (Carlton) 27:231\u2013237. https:\/\/doi.org\/10.1111\/nep.14004","journal-title":"Nephrology (Carlton)"},{"key":"7254_CR18","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1002\/jca.21711","volume":"34","author":"P Khandelwal","year":"2019","unstructured":"Khandelwal P, Thomas CC, Rathi BS et al (2019) Membrane-filtration\u2013based plasma exchanges for atypical hemolytic uremic syndrome: audit of efficacy and safety. J Clin Apher 34:555\u2013562. https:\/\/doi.org\/10.1002\/jca.21711","journal-title":"J Clin Apher"},{"key":"7254_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8070919","volume":"8","author":"ML Gonzalez Suarez","year":"2019","unstructured":"Gonzalez Suarez ML, Thongprayoon C, Mao MA, Leeaphorn N, Bathini T, Cheungpasitporn W (2019) Outcomes of kidney transplant patients with atypical hemolytic uremic syndrome treated with Eculizumab: a systematic review and meta-analysis. J Clin Med 8:919. https:\/\/doi.org\/10.3390\/jcm8070919","journal-title":"J Clin Med"},{"key":"7254_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-003573","volume":"3","author":"J Rathbone","year":"2013","unstructured":"Rathbone J, Kaltenthaler E, Richards A, Tappenden P, Bessey A, Cantrell A (2013) A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS). BMJ Open 3:e003573. https:\/\/doi.org\/10.1136\/bmjopen-2013-003573","journal-title":"BMJ Open"},{"key":"7254_CR21","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000041403","volume":"104","author":"P Meena","year":"2025","unstructured":"Meena P, Gala R, Das RR et al (2025) Kidney and pregnancy outcomes in pregnancy-associated atypical hemolytic uremic syndrome: a systematic review and meta-analysis. Medicine 104:e41403. https:\/\/doi.org\/10.1097\/md.0000000000041403","journal-title":"Medicine"},{"key":"7254_CR22","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1007\/s00431-020-03666-9","volume":"179","author":"\u0160 \u0160tolbov\u00e1","year":"2020","unstructured":"\u0160tolbov\u00e1 \u0160, Bezd\u00ed\u010dka M, Seeman T et al (2020) Molecular basis and outcomes of atypical haemolytic uraemic syndrome in Czech children. Eur J Pediatr 179:1739\u20131750. https:\/\/doi.org\/10.1007\/s00431-020-03666-9","journal-title":"Eur J Pediatr"},{"key":"7254_CR23","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1093\/ckj\/sfaa096","volume":"14","author":"J Portoles","year":"2021","unstructured":"Portoles J, Huerta A, Arjona E et al (2021) Characteristics, management and outcomes of atypical haemolytic uraemic syndrome in kidney transplant patients: a retrospective national study. Clin Kidney J 14:1173\u20131180. https:\/\/doi.org\/10.1093\/ckj\/sfaa096","journal-title":"Clin Kidney J"},{"key":"7254_CR24","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s10157-022-02293-y","volume":"27","author":"A Ashida","year":"2023","unstructured":"Ashida A, Matsumura H, Shimono A, Fujii Y, Yamazaki S (2023) Comparison of outcomes after plasma therapy or eculizumab in pediatric patients with atypical hemolytic uremic syndrome. Clin Exp Nephrol 27:161\u2013170. https:\/\/doi.org\/10.1007\/s10157-022-02293-y","journal-title":"Clin Exp Nephrol"},{"key":"7254_CR25","doi-asserted-by":"publisher","DOI":"10.5001\/omj.2023.117","volume":"38","author":"D Al Riyami","year":"2023","unstructured":"Al Riyami D, Mohammed S, Al Salmi I et al (2023) Epidemiology, management, and outcome of atypical hemolytic uremic syndrome in an Omani cohort. Oman Med J 38:e569-e569. https:\/\/doi.org\/10.5001\/omj.2023.117","journal-title":"Oman Med J"},{"key":"7254_CR26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00467-022-05683-2","volume":"38","author":"RM De Souza","year":"2023","unstructured":"De Souza RM, Correa BHM, Melo PHM et al (2023) The treatment of atypical hemolytic uremic syndrome with eculizumab in pediatric patients: a systematic review. Pediatr Nephrol 38:61\u201375. https:\/\/doi.org\/10.1007\/s00467-022-05683-2","journal-title":"Pediatr Nephrol"},{"key":"7254_CR27","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/j.kint.2017.04.028","volume":"92","author":"V Brocklebank","year":"2017","unstructured":"Brocklebank V, Johnson S, Sheerin TP et al (2017) Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland. Kidney Int 92:1261\u20131271. https:\/\/doi.org\/10.1016\/j.kint.2017.04.028","journal-title":"Kidney Int"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-026-07254-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-026-07254-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-026-07254-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:47:46Z","timestamp":1786978066000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-026-07254-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["7254"],"URL":"https:\/\/doi.org\/10.1007\/s00467-026-07254-1","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,16]]},"assertion":[{"value":"16 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was not required because this study did not include confidential\u00a0participant data.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}